Awakn Life Sciences’ Revenue up 534% in 2022, AUD Treatment Advances

April 30, 2023 · Green Market Report

The firm has made meaningful strides in its early clinical runway as it gears up for government-funded studies.

Toronto-based Awakn Life Sciences Corp. (OTC: AWKNF), a biotech company focused on addiction treatments, reported a heft 534% rise in annual revenue for the fiscal year ended Jan. 31, which they attribute to the strong performance of their clinics.

The company pulled in $1.5 million in annual revenue, a 534% increase year-on-year, with $471,813 in the fourth quarter, a 131% increase sequentially. Net loss for the year was $9.7 million, and improvement versus $16.5 million in 2021.

Awakn had around $550,866 in cash at the end of the period.

“Our clinics delivered strong revenue growth … and looking forward to the current fiscal year, we are targeting a further increase in revenue from our clinics and partnerships,” CEO Anthony Tennyson said in a statement.

Awakn’s main program, AWKN-P001, which aims to treat severe alcohol use disorder (AUD), is moving into phase III. The U.K. government will cover most of the trial costs, leaving Awakn to contribute only $1.25 million.

Additionally, the company is partnering with a European pharmaceutical firm to study the potential of repurposing (S)-ketamine for addiction treatment. Awakn is also working with Catalent on a study of MDMA, using Catalent’s proprietary oral disintegrating tablet technology, which could potentially shorten therapy sessions.

Recently, Awakn received an Innovation Passport – a licensing pathway for pre-clinical ventures – from the U.K. Medicines and Healthcare Products Regulatory Agency for its ketamine-assisted therapy for severe AUD. The company also signed a collaboration agreement with the University of Exeter for an upcoming phase III trial. (Full Story)

In categories:International State Bills
Next Post

Organigram takes Canadian government to court over cannabis lozenge dispute

Canadian marijuana operator Organigram Holdings is asking a federal court to quash a Health Canada decision that the company’s popular ingestible cannabis lozenges should be classified and regulated as edibles instead of extracts. The legal challenge could have broader implications for Canada’s…
Previous Post

Louisiana House Committee Kills Cannabis Legalization Bill

Louisiana lawmakers on Tuesday killed a bill to legalize adult-use cannabis in the state, the Lafayette Daily Advertiser reports. The House Criminal Justice Committee voted down the proposal 9-4.  The measure was opposed by the state’s sheriffs, district attorneys, and police chiefs…
Random Post

Oklahoma Gov. Signs Bill Requiring $50K Bond for Cannabis Cultivators

Oklahoma Gov. Kevin Stitt (R) last week signed a measure requiring all state-approved cannabis growers to hold a $50,000 bond, which lawmakers hope will combat the illegal grows in the state, FOX 23 News reports. The law requires the bond to be…
Random Post

Green Thumb CEO Ben Kovler explains why his marijuana MSO is in the black

When Ben Kovler can’t sleep, it’s a sign that something’s wrong. In 2015, for example, after the Chicago-based marijuana multistate operator won three of the 20 medical cannabis cultivation licenses up for grabs in Illinois, the founder and CEO of…
Random Post

Cannabis lawyer and pot farmer share latest on NY market

There are some growing concerns from New York pot farmers who have more crop than they can sell, as the state’s recreational marijuana market rollout has moved slower than many expected. So far, a dozen retail marijuana stores have opened…
Random Post

Drug that could nip America's fentanyl crisis in the bud: Cannabis compound can help reverse overdoses from the synthetic opioid, study shows

A chemical found in cannabis could be the most effective way to prevent an opioid overdose, scientists believe. Scientists at Indiana University have identified 15 chemicals derived from cannabidiol (CBD) — one of the primary compounds in cannabis — that can reverse…